Database Member Home
RAS Member Home
Building and maintaining effective Key Opinion Leader (KOL) relationships can help drive successful development and commercialization of biopharmaceutical drugs and medical devices. In wake of an increasingly restricted and competitive environment, biopharmaceutical companies must optimize their KOL management structure and responsibility. The best organizational structures for KOL management must align with scientific as well as commercial perspectives.
This video provides inputs on the organizational responsibility for thought leader management, optimal structure for managing Key Opinion Leaders, transparency in engaging with KOLs and the role of Medical Affairs in Key Opinion Leader management.
This video will provide important benchmarks around the responsibility and optimal organizational structure for Thought Leader management.
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Read More »
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)